Which has better earnings and valuation, STRR or SURG?

Star Equity has higher revenue and earnings than SurgePays. Star Equity is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Star Equity $190.35M 0.21 -$5.92M -$2.63 N/A SurgePays $56.96M 0.17 -$36.07M -$1.94 N/A

Is STRR or SURG more profitable?

Star Equity has a net margin of -4.18% compared to SurgePays' net margin of -64.91%. Star Equity's return on equity of -4.04% beat SurgePays' return on equity. Company Net Margins Return on Equity Return on Assets Star Equity -4.18% -4.04% -2.40% SurgePays -64.91% -967.32% -310.16%

Does the media favor STRR or SURG?

In the previous week, Star Equity had 5 more articles in the media than SurgePays. MarketBeat recorded 7 mentions for Star Equity and 2 mentions for SurgePays. Star Equity's average media sentiment score of 1.32 beat SurgePays' score of 1.15 indicating that Star Equity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Star Equity 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SurgePays 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SURG or NTRB?

SurgePays currently has a consensus price target of $3.50, suggesting a potential upside of 782.50%. Given SurgePays' stronger consensus rating and higher possible upside, analysts plainly believe SurgePays is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is SURG or NTRB more profitable?

SurgePays has a net margin of -64.91% compared to Nutriband's net margin of -448.25%. Nutriband's return on equity of -112.64% beat SurgePays' return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% -967.32% -310.16% Nutriband -448.25% -112.64% -97.86%

Does the media prefer SURG or NTRB?

In the previous week, SurgePays had 1 more articles in the media than Nutriband. MarketBeat recorded 2 mentions for SurgePays and 1 mentions for Nutriband. SurgePays' average media sentiment score of 1.15 beat Nutriband's score of 0.64 indicating that SurgePays is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SurgePays 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nutriband 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, TELA or SURG?

SurgePays has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TELA Bio $80.28M 0.44 -$38.83M -$0.79 N/A SurgePays $56.96M 0.17 -$36.07M -$1.94 N/A

Is TELA or SURG more profitable?

TELA Bio has a net margin of -49.30% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of -967.32% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets TELA Bio -49.30% -1,320.81% -55.83% SurgePays -64.91% -967.32% -310.16%

Is SURG or NSPR more profitable?

SurgePays has a net margin of -64.91% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat SurgePays' return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% -967.32% -310.16% InspireMD -413.96% -69.42% -57.68%

Does the media refer more to SURG or NSPR?

In the previous week, SurgePays and SurgePays both had 2 articles in the media. SurgePays' average media sentiment score of 1.15 beat InspireMD's score of 0.00 indicating that SurgePays is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SurgePays 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InspireMD 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, NEPH or SURG?

Nephros has higher earnings, but lower revenue than SurgePays. SurgePays is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nephros $19.12M 1.87 $1.19M $0.07 47.14 SurgePays $56.96M 0.17 -$36.07M -$1.94 N/A

Is NEPH or SURG more profitable?

Nephros has a net margin of 4.06% compared to SurgePays' net margin of -64.91%. Nephros' return on equity of 7.66% beat SurgePays' return on equity. Company Net Margins Return on Equity Return on Assets Nephros 4.06% 7.66% 5.86% SurgePays -64.91% -967.32% -310.16%

Does the media favor NEPH or SURG?

In the previous week, SurgePays had 1 more articles in the media than Nephros. MarketBeat recorded 2 mentions for SurgePays and 1 mentions for Nephros. SurgePays' average media sentiment score of 1.15 beat Nephros' score of 0.03 indicating that SurgePays is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nephros 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SurgePays 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SurgePays (SURG) Competitors

$0.40 -0.01 (-1.37%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$0.41 +0.01 (+3.13%)

As of 04:01 AM Eastern

Compare

SURG vs. STRR, NTRB, TELA, NSPR, and NEPH

Should you buy SurgePays stock or one of its competitors? MarketBeat compares SurgePays with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SurgePays include Star Equity (STRR), Nutriband (NTRB), TELA Bio (TELA), InspireMD (NSPR), and Nephros (NEPH). These companies are all part of the "medical equipment" industry.

How does SurgePays compare to Star Equity?

Star Equity (NASDAQ:STRR) and SurgePays (NASDAQ:SURG) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Star Equity had 5 more articles in the media than SurgePays. MarketBeat recorded 7 mentions for Star Equity and 2 mentions for SurgePays. Star Equity's average media sentiment score of 1.32 beat SurgePays' score of 1.15 indicating that Star Equity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Star Equity	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SurgePays	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Star Equity has higher revenue and earnings than SurgePays. Star Equity is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Star Equity	$190.35M	0.21	-$5.92M	-$2.63	N/A
SurgePays	$56.96M	0.17	-$36.07M	-$1.94	N/A

Star Equity has a net margin of -4.18% compared to SurgePays' net margin of -64.91%. Star Equity's return on equity of -4.04% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Star Equity	-4.18%	-4.04%	-2.40%
SurgePays	-64.91%	-967.32%	-310.16%

Star Equity presently has a consensus price target of $28.00, indicating a potential upside of 154.08%. SurgePays has a consensus price target of $3.50, indicating a potential upside of 782.50%. Given SurgePays' higher possible upside, analysts clearly believe SurgePays is more favorable than Star Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Star Equity	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Star Equity has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, SurgePays has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

3.8% of Star Equity shares are held by institutional investors. Comparatively, 6.9% of SurgePays shares are held by institutional investors. 31.6% of Star Equity shares are held by insiders. Comparatively, 29.1% of SurgePays shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Star Equity beats SurgePays on 12 of the 16 factors compared between the two stocks.

How does SurgePays compare to Nutriband?

SurgePays (NASDAQ:SURG) and Nutriband (NASDAQ:NTRB) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

SurgePays currently has a consensus price target of $3.50, suggesting a potential upside of 782.50%. Given SurgePays' stronger consensus rating and higher possible upside, analysts plainly believe SurgePays is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, SurgePays had 1 more articles in the media than Nutriband. MarketBeat recorded 2 mentions for SurgePays and 1 mentions for Nutriband. SurgePays' average media sentiment score of 1.15 beat Nutriband's score of 0.64 indicating that SurgePays is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SurgePays	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nutriband	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

6.9% of SurgePays shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 29.1% of SurgePays shares are held by company insiders. Comparatively, 52.2% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Nutriband has lower revenue, but higher earnings than SurgePays. Nutriband is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.17	-$36.07M	-$1.94	N/A
Nutriband	$1.80M	20.57	-$8.23M	-$2.58	N/A

SurgePays has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Nutriband has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

SurgePays has a net margin of -64.91% compared to Nutriband's net margin of -448.25%. Nutriband's return on equity of -112.64% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	-967.32%	-310.16%
Nutriband	-448.25%	-112.64%	-97.86%

Summary

SurgePays beats Nutriband on 9 of the 16 factors compared between the two stocks.

How does SurgePays compare to TELA Bio?

TELA Bio (NASDAQ:TELA) and SurgePays (NASDAQ:SURG) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

In the previous week, SurgePays had 2 more articles in the media than TELA Bio. MarketBeat recorded 2 mentions for SurgePays and 0 mentions for TELA Bio. SurgePays' average media sentiment score of 1.15 beat TELA Bio's score of 0.00 indicating that SurgePays is being referred to more favorably in the news media.

Company	Overall Sentiment
TELA Bio	Neutral
SurgePays	Positive

94.4% of TELA Bio shares are owned by institutional investors. Comparatively, 6.9% of SurgePays shares are owned by institutional investors. 5.1% of TELA Bio shares are owned by insiders. Comparatively, 29.1% of SurgePays shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

TELA Bio has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market. Comparatively, SurgePays has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

TELA Bio presently has a consensus price target of $2.20, suggesting a potential upside of 179.97%. SurgePays has a consensus price target of $3.50, suggesting a potential upside of 782.50%. Given SurgePays' higher probable upside, analysts plainly believe SurgePays is more favorable than TELA Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

TELA Bio has a net margin of -49.30% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of -967.32% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-49.30%	-1,320.81%	-55.83%
SurgePays	-64.91%	-967.32%	-310.16%

SurgePays has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.44	-$38.83M	-$0.79	N/A
SurgePays	$56.96M	0.17	-$36.07M	-$1.94	N/A

Summary

TELA Bio beats SurgePays on 9 of the 16 factors compared between the two stocks.

How does SurgePays compare to InspireMD?

SurgePays (NASDAQ:SURG) and InspireMD (NYSE:NSPR) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, SurgePays and SurgePays both had 2 articles in the media. SurgePays' average media sentiment score of 1.15 beat InspireMD's score of 0.00 indicating that SurgePays is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SurgePays	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InspireMD	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

6.9% of SurgePays shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 29.1% of SurgePays shares are held by insiders. Comparatively, 34.1% of InspireMD shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

InspireMD has lower revenue, but higher earnings than SurgePays. InspireMD is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.17	-$36.07M	-$1.94	N/A
InspireMD	$10.85M	3.03	-$19.92M	-$0.73	N/A

SurgePays has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, InspireMD has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

SurgePays presently has a consensus target price of $3.50, suggesting a potential upside of 782.50%. InspireMD has a consensus target price of $4.50, suggesting a potential upside of 541.94%. Given SurgePays' higher possible upside, analysts plainly believe SurgePays is more favorable than InspireMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

SurgePays has a net margin of -64.91% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	-967.32%	-310.16%
InspireMD	-413.96%	-69.42%	-57.68%

Summary

InspireMD beats SurgePays on 10 of the 15 factors compared between the two stocks.

How does SurgePays compare to Nephros?

Nephros (NASDAQ:NEPH) and SurgePays (NASDAQ:SURG) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Nephros has a net margin of 4.06% compared to SurgePays' net margin of -64.91%. Nephros' return on equity of 7.66% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
SurgePays	-64.91%	-967.32%	-310.16%

In the previous week, SurgePays had 1 more articles in the media than Nephros. MarketBeat recorded 2 mentions for SurgePays and 1 mentions for Nephros. SurgePays' average media sentiment score of 1.15 beat Nephros' score of 0.03 indicating that SurgePays is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nephros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SurgePays	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nephros has higher earnings, but lower revenue than SurgePays. SurgePays is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$19.12M	1.87	$1.19M	$0.07	47.14
SurgePays	$56.96M	0.17	-$36.07M	-$1.94	N/A

Nephros presently has a consensus price target of $6.00, suggesting a potential upside of 81.82%. SurgePays has a consensus price target of $3.50, suggesting a potential upside of 782.50%. Given SurgePays' higher possible upside, analysts clearly believe SurgePays is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Nephros has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market. Comparatively, SurgePays has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

41.1% of Nephros shares are held by institutional investors. Comparatively, 6.9% of SurgePays shares are held by institutional investors. 6.7% of Nephros shares are held by insiders. Comparatively, 29.1% of SurgePays shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Nephros beats SurgePays on 10 of the 15 factors compared between the two stocks.

Get SurgePays News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SURG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SURG vs. The Competition

Export

Metric	SurgePays	INTERNET SOFTWARE Industry	Computer Sector	NASDAQ Exchange
Market Cap	$10.10M	$16.09B	$39.32B	$12.38B
Dividend Yield	N/A	3.13%	3.27%	5.83%
P/E Ratio	-0.20	58.63	79.23	23.99
Price / Sales	0.17	44.65	624.50	107.23
Price / Cash	N/A	68.00	48.53	54.51
Price / Book	-0.60	6.19	9.58	6.50
Net Income	-$36.07M	$384.51M	$1.07B	$336.88M
7 Day Performance	-9.86%	-0.36%	-0.81%	-0.16%
1 Month Performance	-21.00%	-4.27%	0.98%	0.76%
1 Year Performance	-86.51%	-10.64%	156.65%	28.49%

SurgePays Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SURG SurgePays	3.6542 of 5 stars	$0.40 -1.4%	$3.50 +782.5%	-85.5%	$10.10M	$56.96M	N/A	40	Positive News
STRR Star Equity	4.3725 of 5 stars	$11.22 +1.8%	$28.00 +149.6%	+462.2%	$41.51M	$172.16M	N/A	1,200	Positive News
NTRB Nutriband	0.6748 of 5 stars	$3.40 -0.4%	N/A	-60.5%	$41.28M	$2.04M	N/A	10	News Coverage
TELA TELA Bio	2.306 of 5 stars	$0.84 +5.1%	$2.20 +161.6%	-54.6%	$37.65M	$80.28M	N/A	120	Positive News
NSPR InspireMD	3.6913 of 5 stars	$0.75 -1.6%	$4.50 +501.6%	-72.2%	$35.04M	$10.85M	N/A	50	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SURG) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SurgePays (SURG) Competitors

SURG vs. STRR, NTRB, TELA, NSPR, and NEPH

How does SurgePays compare to Star Equity?

Summary

How does SurgePays compare to Nutriband?

Summary

How does SurgePays compare to TELA Bio?

Summary

How does SurgePays compare to InspireMD?

Summary

How does SurgePays compare to Nephros?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SURG vs. The Competition

SurgePays Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SurgePays (SURG) Competitors

SURG vs. STRR, NTRB, TELA, NSPR, and NEPH

How does SurgePays compare to Star Equity?

Does the media favor STRR or SURG?

Which has better earnings and valuation, STRR or SURG?

Is STRR or SURG more profitable?

Do analysts recommend STRR or SURG?

Which has more risk & volatility, STRR or SURG?

Do institutionals and insiders believe in STRR or SURG?

Summary

How does SurgePays compare to Nutriband?

Do analysts prefer SURG or NTRB?

Does the media prefer SURG or NTRB?

Do insiders & institutionals have more ownership in SURG or NTRB?

Which has better valuation & earnings, SURG or NTRB?

Which has more risk and volatility, SURG or NTRB?

Is SURG or NTRB more profitable?

Summary

How does SurgePays compare to TELA Bio?

Does the media favor TELA or SURG?

Do institutionals & insiders hold more shares of TELA or SURG?

Which has more volatility and risk, TELA or SURG?

Do analysts recommend TELA or SURG?

Is TELA or SURG more profitable?

Which has stronger earnings and valuation, TELA or SURG?

Summary

How does SurgePays compare to InspireMD?

Does the media refer more to SURG or NSPR?

Do insiders & institutionals hold more shares of SURG or NSPR?

Which has higher earnings and valuation, SURG or NSPR?

Which has more risk and volatility, SURG or NSPR?

Do analysts prefer SURG or NSPR?

Is SURG or NSPR more profitable?

Summary

How does SurgePays compare to Nephros?

Is NEPH or SURG more profitable?

Does the media favor NEPH or SURG?

Which has better earnings and valuation, NEPH or SURG?

Do analysts prefer NEPH or SURG?

Which has more risk & volatility, NEPH or SURG?

Do insiders and institutionals have more ownership in NEPH or SURG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SURG vs. The Competition

SurgePays Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools